Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
GlaxoSmithKline |
---|---|
Information provided by: | GlaxoSmithKline |
ClinicalTrials.gov Identifier: | NCT00555035 |
To determine safety, tolerability and pharmacokinetics of GSK1349572
Condition | Intervention | Phase |
---|---|---|
Healthy Subjects |
Drug: GSK1349572 |
Phase I |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double-Blind, Parallel Assignment, Safety Study |
Official Title: | A Double-Blind, Randomized, Placebo-Controlled, Single Dose Escalation Study to Investigate the Safety, Tolerability and Pharmacokinetics of GSK1349572 in Healthy Subjects |
Enrollment: | 20 |
Study Start Date: | November 2007 |
Study Completion Date: | February 2008 |
Primary Completion Date: | February 2008 (Final data collection date for primary outcome measure) |
Ages Eligible for Study: | 18 Years to 55 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | Yes |
Inclusion criteria:
A female is eligible to enter and participate in this study if she is of non-childbearing potential (i.e., physiologically incapable of becoming pregnant), including any female who:
Exclusion criteria:
Exclusion Criteria for 24-Hour Screening Holter:
Responsible Party: | GSK ( Study Director ) |
Study ID Numbers: | ING111207 |
Study First Received: | November 5, 2007 |
Last Updated: | October 9, 2008 |
ClinicalTrials.gov Identifier: | NCT00555035 |
Health Authority: | United States: Food and Drug Administration; United States: Food and Drug Administration |
GSK1349572, healthy volunteers |
Healthy |